KemPharm to Host Investor Conference Call Detailing Plans for Pipeline Expansion
January 12 2022 - 7:30AM
KemPharm, Inc. (NasdaqGS: KMPH), a specialty pharmaceutical
company focused on the discovery and development of proprietary
prodrugs, today announced that the Company will host a conference
call and live audio webcast on Wednesday, January 19, 2022, at
4:30 p.m. ET, to discuss the Company’s strategy for advancing and
expanding its development pipeline. During the call,
senior management will provide guidance regarding KemPharm’s future
clinical development priorities.
Conference Call
Information:
Telephone Access: |
To access the conference call telephonically, interested
participants and investors will be required to register via the
following online form:
http://www.directeventreg.com/registration/event/1793309Once
registered, all individuals will be provided with participant
dial-in numbers, a passcode and a registrant ID, which can then be
used to access the conference call. Participants may register at
any time. It is recommended that the registration process be
completed at least 15 minutes prior to the start of the call. |
|
|
Webcast Access: |
The live audio webcast with slide presentation will be accessible
via the Investor Relations section of KemPharm’s
website, http://investors.kempharm.com/. An archive of the
webcast and presentation will be available for 90 days beginning at
approximately 5:30 p.m. ET, on January 19, 2022. |
About KemPharm:
KemPharm is a specialty pharmaceutical company
focused on the discovery and development of proprietary prodrugs to
treat serious medical conditions through its proprietary LAT®
(Ligand Activated Therapy) technology. KemPharm utilizes its
proprietary LAT® technology to generate improved prodrug versions
of FDA-approved drugs as well as to generate prodrug versions of
existing compounds that may have applications for new disease
indications. KemPharm’s prodrug product candidate pipeline is
focused on the high need areas of attention deficit hyperactivity
disorder, or ADHD, stimulant use disorder (SUD) and CNS rare
diseases, including idiopathic hypersomnia (IH). In addition, the
U.S. Food and Drug Administration (FDA) has approved AZSTARYS®, a
new once-daily treatment for ADHD in patents age six years and
older containing KemPharm’s prodrug, serdexmethylphenidate (SDX),
and APADAZ®, an immediate-release combination product containing
benzhydrocodone, KemPharm’s prodrug of hydrocodone, and
acetaminophen. For more information on KemPharm and its pipeline of
prodrug product candidates visit www.kempharm.com or connect with
us on Twitter, LinkedIn, Facebook and YouTube.
KemPharm Contacts:
Tiberend Strategic Advisors, Inc.Jason
Rando/Maureen McEnroe, CFA(212) 375-2665 /
2664jrando@tiberend.commmcenroe@tiberend.com
KemPharm (NASDAQ:KMPH)
Historical Stock Chart
From Mar 2024 to Apr 2024
KemPharm (NASDAQ:KMPH)
Historical Stock Chart
From Apr 2023 to Apr 2024